BLU-020
/ Sanofi, Blueprint Medicines
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
The discovery of BLU-020: A potent and selective degrader of CDK2 for the treatment of CCNE1 aberrant cancers
(AACR 2026)
- "With its potency on CDK2 and improved selectivity over other CDK family members and the kinome compared to previous reported CDK2 agents, BLU-020 has best-in-class potential for CCNE1-aberrant ovarian cancers."
Oncology • Ovarian Cancer • Solid Tumor • CCNE1 • CDK2 • CDK4
1 to 1
Of
1
Go to page
1